Andrew Left

Andrew Left
Born	Andrew Edward Left 7/9/1970
Birthplace	Michigan, U.S.
Nationality	American
Occupation	Financial analyst, financial writer, short seller
Known for	Activist short selling, founder of Citron Research
Alma mater	Northeastern University

Andrew Edward Left (born July 9, 1970) is an American activist short seller, financial analyst, and the founder and editor of Citron Research, an online investment research publication that started as StockLemon.com. He's made a career publishing investigative reports on publicly traded companies he believes are overvalued, engaging in fraud, or operating under shady business practices. His targets have ranged across S&P 500 firms to several Chinese companies listed on American exchanges, and his reports have occasionally triggered massive declines in share prices. Left shows up constantly on CNBC and Bloomberg to discuss specific stocks and short selling generally. In 2017, The New York Times called him "The Bounty Hunter of Wall Street." His record includes real wins, like his short position in Valeant Pharmaceuticals that turned out prescient, but also serious legal battles: a five-year trading ban in Hong Kong and 2024 federal criminal charges alleging securities fraud and market manipulation. He's fighting those charges in what's become an ongoing trial in 2026.

Early Life

Andrew Edward Left was born on July 9, 1970, in Michigan. Not much is publicly known about his childhood or family. He grew up in Michigan before heading to university in the Northeast.

Education

Left went to Northeastern University in Boston, Massachusetts, for his undergraduate degree. The school's cooperative education program, which combines classroom learning with paid professional work experience, gave him early exposure to finance.

Career

Early Career and National Futures Association Sanction

Left started working in finance in the mid-1990s. He traded futures before founding Citron Research. During those early years, the National Futures Association (NFA), the self-regulatory organization for the U.S. derivatives industry, sanctioned him. They said Left "made false and misleading statements to cheat, defraud or deceive a customer in violation of NFA compliance rules." This early action would set the tone for his contentious history with financial regulators.

Founding of Citron Research

He launched his online investment research operation as StockLemon.com, later rebranding it as Citron Research. Through this vehicle, Left could publish investigative reports on publicly traded companies. Unlike traditional Wall Street research shops, Citron operates as an independent, outsider outfit. Left's approach is straightforward: research companies he thinks are overvalued or fraudulent, publish the findings, and short the stock so he profits if it falls.

Citron published 51 reports targeting S&P 500 companies over the years. The allegations were varied: pyramid schemes, ineffective products, accounting fraud, business fraud. Left also went after Chinese companies on U.S. exchanges, becoming part of the broader scrutiny around Chinese financial reporting standards and the practices of firms raising capital in America.

Companies sued. Multiple companies. But Left has never lost a lawsuit in the United States, or so he claims.

Evergrande Group Report and Hong Kong Ban

In June 2012, Citron published a report on Chinese property developer Evergrande Group, alleging fraud. The stock tanked after the report came out.

Hong Kong's Market Misconduct Tribunal, chaired by Justice Michael Hartmann, investigated. By 2016, they'd banned Left from trading in Hong Kong for five years. The Tribunal found he'd disclosed false or misleading information about Evergrande, violating the Securities and Futures Ordinance. Here's the ironic part: Left's thesis about Evergrande was actually right. The company defaulted years later in a catastrophic collapse that shook global markets. His punishment wasn't rescinded. The case showed something important about short selling: the truth of your allegations doesn't always matter legally if you disclosed information improperly.

Valeant Pharmaceuticals

Left's most important work came in October 2015. Citron published a report on Valeant Pharmaceuticals International (later renamed Bausch Health Companies) that compared the company's practices to Enron. Left alleged Valeant's relationship with specialty pharmacy Philidor Rx Services was a scheme to inflate revenues, and that the company's whole business model of acquiring firms and jacking up drug prices couldn't hold.

The effect was immediate. Stock price crashed. Bill Ackman, the billionaire hedge fund manager whose Pershing Square Capital Management had a huge long position in Valeant, took enormous losses as shares plummeted. Billions of dollars in market value vanished once the short-selling campaign kicked in and the company's practices came to light.

The Los Angeles Times dug into the scandal in detail, showing how Left's initial allegations opened the door to wider questions about drug pricing, corporate governance, and Valeant's specialty pharmacy network. By March 2016, Left was calling Valeant "uninvestable," sticking to his thesis even as some investors bet on recovery. Fortune chronicled the Valeant timeline, which became one of the defining corporate scandals of the mid-2010s.

The Valeant campaign cemented his status as one of America's most influential activist short sellers. It proved that independent research could take on big corporations and win.

Mallinckrodt Pharmaceuticals

November 2015. Left turned his attention to Mallinckrodt Pharmaceuticals, another pharmaceutical company with practices he found problematic. Citron tweeted about Mallinckrodt's H.P. Acthar Gel, priced at roughly $35,000. Bloomberg reported that a single tweet from Left was enough to put pharmaceutical pricing back in the headlines.

Legal Battles With Target Companies

Left's been sued by many companies. These lawsuits have tested free speech, securities law, and what short sellers can say about public companies.

GTX Global Corp. sued him in response to Citron's research. The Digital Media Law Project documented the case as an example of legal risk for activist short sellers. He's also faced litigation over research on disaster rebuilding companies, as the Times-Picayune of New Orleans reported.

Internet law case archives show more litigation, reflecting a pattern where companies tried to use courts to shut down critical short-seller research.

Left says he's never lost a U.S. lawsuit related to his research publications.

Federal Criminal Charges (2024–present)

July 2024 brought federal charges. Prosecutors alleged Left had illegally manipulated markets by publishing research and then trading against those positions. The indictment was a major escalation and raised serious questions about what activist short selling can legally do.

His legal team filed motions to dismiss, arguing the conduct fell within lawful market commentary and trading. In December 2025, a judge rejected the bid to dismiss. Prosecution could proceed to trial.

November 2025 brought another development. Left petitioned the SEC to define illegal "scalping"—recommending one position publicly while trading the opposite way privately. He sought guidance that might clarify the law and potentially undermine the government's case.

In December 2025, Business Insider reported something unusual: Left was using the AI chatbot Claude to prepare for trial. He'd been discussing legal strategy and case concerns with the system. The report highlighted how a defendant in a major securities fraud case was turning to artificial intelligence for help structuring his defense.

February 2026. The case is still pending. Left faces a trial expected to set important legal precedent.

Personal Life

Left lives in the United States. Not much is publicly known about his personal or family life. He's kept a low profile outside his professional work, mostly appearing through Citron Research and media interviews about financial markets.

Recognition

His activist short-selling work has gotten significant media attention. Both positive and negative. In 2017, The New York Times profiled him as "The Bounty Hunter of Wall Street," a label reflecting his reputation for targeting companies he saw as fraudulent or drastically overpriced.

He appears regularly on CNBC, Bloomberg Television, and financial news shows discussing his research and stock picks. The Valeant campaign especially made him one of the most recognized activist short sellers in America.

Bloomberg has covered his work many times, including Valeant, Mallinckrodt, and other companies. The Motley Fool's CAPS community has documented cases where Citron's theses turned out right.

His career's polarizing. The Hong Kong ban, the early NFA action, the 2024 indictment. Supporters see him as an independent watchdog exposing real fraud. Critics question his methods and whether his public research aligns with his private trading.

Legacy

Left's work through Citron intersected with several major financial controversies of the 2010s and 2020s. Valeant became one of the decade's most notorious pharmaceutical scandals, partly thanks to his research. Evergrande's 2012 report preceded by nearly ten years the company's historic default and China's broader real estate crisis.

His work sparked ongoing debate about short selling's role in markets. Supporters argue researchers like Left serve a critical function by spotting overvaluation and fraud that traditional analysts miss, especially analysts conflicted by investment banking relationships. Opponents contend activist short sellers manipulate markets by publishing negative reports designed to drive prices down for profit.

The federal case pending in early 2026 could set important legal precedent on where activist short selling ends and illegal manipulation starts. Securities regulators, hedge funds, short sellers, and legal scholars will watch closely. The outcome matters a lot.

Left's use of social media and online publishing to spread financial research, starting with StockLemon.com's early days, anticipated the broader democratization of investment research in the 21st century. Citron's model of publishing free, opinionated research online rather than through Wall Street channels has been copied by many independent research operations.